Portal de investigación
Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
Fecha de publicación:
Autores de I3PT
Participantes ajenos a I3PT
- Salvador-Martin, S
- Raposo-Gutierrez, I
- Navas-Lopez, VM
- Gallego-Fernandez, C
- Moreno-Alvarez, A
- Solar-Boga, A
- Munoz-Codoceo, R
- Magallares, L
- Martinez-Ojinaga, E
- Fobelo, MJ
- Millan-Jimenez, A
- Rodriguez-Martinez, A
- Vayo, CA
- Sanchez, C
- Tolin, M
- Bossacoma, F
- Pujol-Muncunill, G
- de Caldas, RG
- Blanca-Garcia, JA
- Segarra, O
- Eizaguirre, FJ
- Garcia-Romero, R
- Merino-Bohorquez, V
- Sanjurjo-Saez, M
- Lopez-Fernandez, LA
Grupos de Investigación
Abstract
Around a 20-30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30% of patients do not respond. The aim of the work was to identify markers that would predict an early response to anti-TNF drugs in pediatric patients with IBD. The study population included 43 patients aged <18 years with IBD who started treatment with infliximab or adalimumab. Patients were classified into primary responders (n = 27) and non-responders to anti-TNF therapy (n = 6). Response to treatment could not be analyzed in 10 patients. Response was defined as a decrease in over 15 points in the disease activity indexes from week 0 to week 10 of infliximab treatment or from week 0 to week 26 of adalimumab treatment. The expression profiles of nine genes in total RNA isolated from the whole-blood of pediatric IBD patients taken before biologic administration and after 2 weeks were analyzed using qPCR and the 2(-Ct) method. Before initiation and after 2 weeks of treatment the expression of SMAD7 was decreased in patients who were considered as non-responders (p value < 0.05). Changes in expression were also observed for TLR2 at T0 and T2, although that did not reach the level of statistical significance. In addition, the expression of DEFA5 decreased 1.75-fold during the first 2 weeks of anti-TNF treatment in responders, whereas no changes were observed in non-responders. Expression of the SMAD7 gene is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD. TLR2 and DEFA5 need to be validated in larger studies.
Datos de la publicación
- ISSN/ISSNe:
- 1661-6596, 1422-0067
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.3390/ijms21093364
- PubMed:
- 32397546
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES MDPI
Citas Recibidas en Web of Science: 19
Documentos
- No hay documentos
Filiaciones
Keywords
- biomarker; gene expression; infliximab; adalimumab; ulcerative colitis; Crohn's disease
Campos de Estudio
Financiación
Cita
Salvador S,Raposo I,Navas VM,Gallego C,Moreno A,Solar A,Munoz R,Magallares L,Martinez E,Fobelo MJ et al. Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease. Int. J. Mol. Sci. 2020. 21. (9):3364. DOI: 10.3390/ijms21093364.
Salvador S,Raposo I,Navas VM,Gallego C,Moreno A,Solar A,Munoz R,Magallares L,Martinez E,Fobelo MJ,Millan A,Rodriguez A,Vayo CA,Sanchez C,Tolin M,Bossacoma F,Pujol G,de Caldas RG,Loverdos I,Blanca JA,Segarra O,Eizaguirre FJ,Garcia R,Merino V,Sanjurjo M,Lopez LA. Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease. Int. J. Mol. Sci. 2020. 21. (9):3364. IF:5,923. (1).